Site icon ViralPosts

Phase III trial of Bharat Biotech’s Nasal Corona Vaccine completed, may be launched soon

“We just finished a clinical experiment,” Dr. Ella stated. “A data analysis is underway, and we will submit the data to the regulatory agency next month.” If all goes well, permission will be granted.”

The Phase III study of the COVID-19 nasal vaccination has been finished, according to Bharat Biotech Chairman and Managing Director Krishna Ella, and the business will submit its results to Next month, the Drug Controller General of India (DCGI) will be appointed. “The clinical trial was recently completed, data processing is underway, and the data will be submitted to the regulatory authorities next month,” Dr. Ella revealed in an exclusive interview. We’ll acquire authorization and launch if all goes smoothly.” Vaccine. This will be the world’s first COVID-19 nasal vaccine that has been clinically proved.”

a booster dose should be taken

Dr. Ella was speaking at Viva Technology 2022 in Paris, where India was named Country of the Year. It is to be known that in January this year, the Drug Controller of India allowed Bharat Biotech to conduct standalone Phase III trials on its nasal corona vaccine. On the booster dose of Kovid-19, Dr. Ella said that those who have taken the second dose must definitely take the booster dose.

Read More: These 4 sub-variants of Omicron are behind the new wave of corona in the country, see in which states the infection is increasing.

Corona will never end completely

“A booster dose of vaccine provides immunity,” he explained. I always say that a booster dose for every vaccination is a miracle dose. Even in the first children, two doses do not give much immunity, but in children, the third dose gives an amazing response.” It has to be handled more intelligently.”

 Join Our Group For All Information And Update, Also Follow me For Latest Information
 Facebook Page                  Click Here
 Twitter                               Click Here
 Instagram                  Click Here
 Google News                  Click Here
Exit mobile version